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Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via
inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option. The TOPARP-A
clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate
cancer. However, several unanswered questions regarding the use of olaparib remain: 1) How do we best stratify
patients for olaparib treatment? 2) Where do we place olaparib in the treatment sequence paradigm? 3) Is there
cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance
between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models.
Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP
trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and
olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or
enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells
than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could
blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.
Translational Oncology 12, 871–878(2019)dress all correspondence to: Allen C. Gao, Research III, Suite 1300, 4645 2nd
enue, Sacramento, CA 95817. E-mail: acgao@ucdavis.edu
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en access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-
-nd/4.0/).
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astration-resistant prostate cancer (CRPC) remains an incurable disease
sponsible for significant morbidity and mortality. Recent efforts have
ded several therapies to the armamentarium for CRPC including the
xt-generation antiandrogen therapies, enzalutamide and abiraterone,
d the taxanes docetaxel and cabazitaxel [1–4]. Despite these advances,
tients still succumb to the disease, highlighting the urgent need for both
vel therapies and research to understand the optimal sequencing of all
ailable options for patients.
Inhibition of poly (ADP-ribose) polymerase (PARP) using small
olecule PARP inhibitors (PARPis) is quickly emerging as an
ficacious treatment option for CRPC [5]. The PARP family consists17 members, each of which possesses ADP-ribose transfer function
,7]. Adding chains of ADP-ribose is known as poly ADP-
bosylation (PARylation). PARylation can alter the functioning of
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872 Mechanisms of Olaparib-Taxane Cross-Resistance Lombard et al. Translational Oncology Vol. 12, No. 7, 2019veral different substrates and is involved in numerous cellular
ocesses. A key function of PARP is to detect and initiate repair of
ngle-strand DNA breaks [8]. Inhibition of PARP activity leads to
creased DNA repair stress and the creation of double-strand breaks
hich must be repaired by additional mechanisms such as
mologous recombination [7]. In the context of cells with mutations
alterations to DNA-repair proteins, loss of PARP activity can lead
synthetic lethality [9,10]. PARPi treatment is emerging to exploit
is synthetic lethality effect in select tumors with defined DNA-
pair defects such as mutations in BRCA1 and BRCA2. While initial
search is promising, further research is needed to fully understand
ARPi function in varying contexts as this will improve our ability to
eat patients.
Several PARPis are now in clinical development with exciting results in
rying cancer indications. Notably, the TOPARP-A study tested the
ARPi olaparib in the context of metastatic CRPC [11]. Fifty patients
ere recruited and treated with olaparib along with extensive genomic
sting for biomarkers of DNA-repair deficiency. Of 49 evaluable
tients, 16 were documented as having had a response. Of those 16
tients, 14 were determined to have a DNA-repair defect, suggesting
at biomarker stratification may highlight a subset of patients who will
ve a response to PARPis. These results indicate the promise of using
ARPis in CRPC clinical practice, but questions still abound regarding
eir use in this indication. It is noted that 2 of the 16 responders were not
termined to be biomarker positive, and it was suggested that some
tients considered biomarker positive had only single allele alterations
hich may not be sufficient to induce functional deficiency [7]. This
ggests that further work is needed to fully understand response to these
ugs. Also, the patient population recruited for this trial had been heavily
etreated with other approved CRPC treatments [11]. One hundred
rcent of patients had previously received docetaxel, while varying
rcentages had also been given abiraterone, enzalutamide, and
bazitaxel. It is currently unknown how prior therapeutic exposure
ay impact response to PARPis, nor is it understood where best to place
ARPis or how best to utilize them in the CRPC clinical treatment
radigm. Our previous work demonstrated select cross-resistance
tween currently used CRPC treatments [12,13]. Studies to evaluate
tative cross-resistance between these therapies and PARPis are lacking.
Due to the promise of using olaparib in CRPC based on the
OPARP-A trial, olaparib received FDA breakthrough therapy
signation, paving the way for a possible approval for this indication.
udies to understand how to use and sequence olaparib with other
proved therapies are warranted to allow for maximized clinical
ficacy. In this study, we assess the ability of olaparib to treat varying
odels of treatment resistant CRPC to understand putative cross-
sistance. We find that taxane resistance induces robust cross-
sistance to olaparib and that this is mediated by increased ABCB1
pression. Inhibition of ABCB1 resensitizes resistant cells to
eatment. We also show that putative olaparib combination therapies
ay be highly effective in olaparib-resistant and -sensitive tumors.
aterials and Methods
ell Culture and Reagents
C4-2B cells were kindly provided and authenticated by Dr. Leland
hung (Cedars-Sinai Medical Center, Los Angeles, CA). DU145
lls were obtained from the American Type Culture Collection,
hich uses short tandem repeat profiling for testing and authenti-
tion of cell lines. All cell lines are routinely tested for mycoplasmaing ABM mycoplasma PCR detection kit (cat. #G238). All
periments with these cell lines and their derivatives were conducted
ithin 6 months of receipt or resuscitation after cryopreservation.
ells were maintained in RPMI 1640 media supplemented with 10%
tal bovine serum, 100 IU penicillin, and 0.1 mg/ml streptomycin.
nzalutamide-resistant C4-2B cells (C4-2B-MDVR), abiraterone-
sistant C4-2B cells (C4-2B-AbiR), docetaxel-resistant C4-2B cells
4-2B-TaxR), and DU145-DTXR cells were characterized and
scribed previously and maintained in complete RPMI 1640
pplemented with 20 μM enzalutamide, 10 μM abiraterone, or 5
docetaxel (TaxR and DU145-DTXR), respectively [14–16]. C4-
and DU145 parental cells were cultured alongside derivative cell
es during their creation as an appropriate control. TaxR-Control
d TaxR-shABCB1 were described previously and maintained in
mplete RPMI 1640 supplemented with 2 μg/ml puromycin [16].
abR cells were created through continuous culture of TaxR cells in
creasing doses of cabazitaxel over a 3-month period. CabR cells are
aintained in complete RPMI 1640 supplemented with 5 nM
bazitaxel. All cells were maintained at 37°C in a humidified
cubator with 5% carbon dioxide. Docetaxel (cat. #RS019) was
rchased from TSZ CHEM. Enzalutamide (cat. #S1250), olaparib
at. #S1060), and cabazitaxel (cat. #S3022) were purchased from
lleckchem. Abiraterone Acetate (cat. #X6144) was purchased from
K Scientific, Inc. Elacridar (cat. #143664-11-3) was purchased from
gma-Aldrich. Puromycin (cat. #BP2956-100) was purchased from
hermoFisher Scientific. Methyl methanesulfonate (MMS; 99%)
at. #156890050) was purchased from Fisher Scientific.
ell Growth Assay
Cells were plated at a density of 25,000 cells/well in 24-well plates in
mplete RPMI 1640media without any selection agent. After 24 hours,
lls were subjected to indicated treatments. All drugs were administered
multaneously in each given assay. Total cells were counted via Coulter
unter 72 hours posttreatment. Alternatively, cell proliferation was
easured using Cell Counting Kit-8 (cat. #CK04) purchased from
ojindo Laboratories using manufacturer's instructions. Data are
splayed as percent of control cell growth − treatment group cell
mber/control group cell number × 100. All conditions were performed
triplicate. All experiments were performed at least twice.
olony Formation Assay
Cells were plated at 500 cells/well in 6-well plates in complete
PMI 1640 with no selection agent. Plated cells were subsequently
eated 24 hours later as indicated. All drugs were administered
multaneously in each given assay. Colonies formed for 14 days. At
e completion of each assay, cell colonies were fixed and stained
ing the following solution for 20 minutes: 0.05% w/v crystal violet,
of 37% formaldehyde, 1% methanol, 1× PBS. After staining,
lonies were rinsed, allowed to air dry, and counted. Data are
splayed as a percent of control cell colony growth (control is vehicle
eatment only). All conditions were performed in duplicate. All
periments were performed at least twice.
reparation of Whole Cell Lysates and Chromatin-Bound
raction
Cells were harvested, washed with PBS, and lysed in RIPA buffer
pplemented with 0.5 mM EDTA, 1 mM NaV, 10 mM NaF, and
Halt Protease Inhibitor Cocktail (cat. #78430) purchased from
hermoFisher Scientific. Protein concentration was determined with
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Translational Oncology Vol. 12, No. 7, 2019 Mechanisms of Olaparib-Taxane Cross-Resistance Lombard et al. 873erce Coomassie Plus (Bradford) Assay Kit (cat. #23236) purchased
om ThermoFisher Scientific. Chromatin-bound protein fractions
ere isolated using the Subcellular Protein Fractionation Kit for
ultured Cells (cat. #78840) purchased from ThermoFisher
ientific and used according to manufacturer's protocol.
estern Blot
Protein extracts were resolved by SDS-PAGE, and indicated primary
tibodies were used. For PAR analysis, cells were first treated with
dicated doses of olaparib for 30 minutes prior to harvest. For PARP
apping analysis, cells were first treated with 0.01%MMS and indicated
ses of olaparib for 4 hours prior to harvest. Antibodies used were as
llows: ABCB1 antibody (SC-8313, rabbit-polyclonal, 1:500 dilution)
as purchased from Santa Cruz Biotechnology; PARP antibody (CS-
32S, rabbit-monoclonal antibody, 1:1000 dilution) was purchased
omCell Signaling Technology; PAR antibody (4335-MC-100, mouse-
onoclonal antibody, 1:1000 dilution) was purchased from Trevigen;
ubulin antibody (T5168, mouse monoclonal antibody, 1:6000
lution) was purchased from Sigma-Aldrich; GAPDH antibody
AB374, mouse monoclonal antibody, 1:10000) was purchased from
MDMillipore; and Histone-H3 antibody (cat. #39163) was purchased
om Active Motif. Tubulin and Histone-H3 were used to monitor the
ounts of samples applied. Proteins were visualized with a chemilumi-
scence detection system (cat. #WBLUR0500) purchased from
illipore. Densitometry to quantify blots was performed using ImageJ.
atistics
All quantitated data are displayed as percent of control mean ±
andard deviation. Significance was assessed using a two-tailed, two-gure 1. Response to olaparib is blunted in models of therapeutic-resis
aparib in MDVR, AbiR, and TaxR cells versus parental C4-2B cells usin
ere calculated and are represented in the table. (B) Colony formation a
rental C4-2B cells. Quantification of the assay is shown (right panel)mple, equal-variance Student’s t test. A P value of ≤ .05 was
cepted as significant.
esults
laparib Efficacy Is Blunted in Models of Treatment-Resistant
RPC
While recent clinical work has shown the potential utility of using
aparib to treat advanced CRPC, it is not known where in the
eatment sequence this drug should be used, nor has it been
termined how previous exposure to different drugs will affect its
ficacy [11]. We hypothesized that cross-resistance may exist
tween olaparib and currently approved CRPC treatments. We
ve created and characterized several models of CRPC therapeutic
sistance using C4-2B as a parental cell line: enzalutamide-resistant
4-2B-MDVR cells (MDVR), abiraterone-resistant C4-2B-AbiR
lls (AbiR), and docetaxel-resistant C4-2B-TaxR cells (TaxR)
4–16]. Using these models, we tested response to olaparib in the
ntext of therapeutic resistance.
Cell growth assays and determination of IC50s demonstrate
fferential olaparib responses in varying resistant models versus
rental C4-2B cells (Figure 1A). While AbiR cells remain relatively
nsitive to olaparib, MDVR cells do exhibit moderate cross-
sistance to the treatment. In contrast, TaxR cells exhibit robust
sensitivity to olaparib treatment, prompting additional study. To
rther test TaxR cross-resistance to olaparib, we used colony
rmation assays (Figure 1B). While olaparib markedly reduced
lony-forming ability in C4-2B cells, this effect was largely bluntedtant CRPC. (A) Cell growth assays were used to test response to
g indicated doses of olaparib over a 72-hour period. IC50 values
ssays were used to test response to olaparib in TaxR cells versus
. Ola = olaparib, * = P value ≤ .05.
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Figure 2. Assessment of olaparib mechanistic function in TaxR vs. C4-2B cells. (A) C4-2B and TaxR cells were treated with increasing
doses of olaparib for 30 minutes. Cells were then harvested and whole cell lysates were subjected to Western blot for PAR (upper panel).
GAPDH served as a loading control. Densitometric quantification of the blot is shown (lower panel). PAR levels are normalized to GAPDH
expression. (B) C4-2B and TaxR cells were treated with 0.01% MMS and indicated doses of olaparib for 4 hours and then harvested and
fractionated to isolate the chromatin-bound fraction. Chromatin-bound fraction was subjected to Western blot for PARP. Histone-H3
served as a loading control. Ola = olaparib, Ab = antibody used.
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eatly retard responses to subsequent treatment with olaparib.ab
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colaparib PARP Trapping Is Blunted in Docetaxel-Resistant
RPC Cells
PARP inhibitors such as olaparib are known to exert their effects in two
ays: 1) inhibition of PARP catalytic function and 2) trapping of PARP
chromatin leading to DNA damage and apoptosis [17,18]. To better
derstand olaparib cross-resistance in TaxR cells, we first tested whether
aparib's inhibition of PARP catalytic activity was altered usingWestern
ots for PAR to assess the relative level of inhibited PARylation
igure 2A). C4-2B and TaxR cells were treated with indicated doses of
aparib for 30 minutes prior to harvest, and then whole cell lysates were
bjected to Western blot for PAR. Quantification of the blots is also
own. Interestingly, we found a similar decrease in PAR levels in
sponse to treatment with increasing doses of olaparib, suggesting no
gnificant difference in olaparib's ability to inhibit PARP catalytic activity
these doses in TaxR cells versus parental C4-2B cells. To assess whether
e levels of trapped PARPwere altered, we treated C4-2B andTaxR cells
ith 0.01%MMS to recruit PARP to damagedDNA and subjected each
ll line to increasing doses of olaparib to trap PARP at sites of damage
8]. After 4 hours of treatment, we isolated the chromatin-bound cellular
actions and performedWestern blots for PARP (Figure 2B). We found
at in olaparib-sensitive C4-2B cells, treatment with increasing olaparibncentrations led to increased trapped PARP. However, in TaxR cells,
apped PARP levels were unchanged. These data suggest that olaparib's
ility to lock PARP onto DNA is blunted in docetaxel-resistant prostate
ncer, and this may be responsible for cross-resistance between
ese therapies.BCB1 Mediates Robust Resistance to Olaparib
Our data suggest that prior exposure to taxane chemotherapy
duces cross-resistance to olaparib. We've shown previously that
xane-resistant TaxR cells become cross-resistant to both docetaxel
d cabazitaxel through increased levels of ABCB1 compared to
ntrol C4-2B cells [13,16]. We hypothesize that ABCB1-mediated
xane cross-resistance may additionally induce resistance to olaparib
CRPC cells. Western blot for ABCB1 confirms our previous data
owing TaxR cells have increased ABCB1 expression (Figure 3A).
hether ABCB1 confers resistance to olaparib in CRPC is unknown.
To test the role of ABCB1 inmediating cross-resistance to olaparib, we
st used two additional models: 1) a DU145-derived docetaxel-resistant
ll line, DU145-DTXR, which we've previously demonstrated also
ssesses augmented ABCB1 levels versus parental DU145 cells, and 2) a
vel cabazitaxel-resistant cell line, CabR, derived from docetaxel-
sistant TaxR cells (Supplemental Figure 1) [13,16]. Western blots
nfirm increased ABCB1 expression in DU145-DTXR cells versus
ntrol cells and also show that CabR cells further increase ABCB1
ex
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de
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da
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Figure 3. IncreasedABCB1expression is associatedwith resistance to olaparib. (A)Whole cell lysates from indicated cell lineswere subjected to
Western blot for ABCB1. Tubulin served as a loading control. (B) Cell growth assay was used to test response to olaparib in docetaxel-resistant
DU145-DTXR cells versus parental DU145 cells. Western blot was used to assess ABCB1 expression in these cell lines. Tubulin served as a
loading control. (C) Cell growth assaywas used to test response to olaparib in cabazitaxel-resistant CabR cells.Western blot was used to assess
ABCB1 expression in C4-2B, TaxR, and CabR cells. Tubulin served as a loading control. Ola = olaparib, Ab = antibody used, * = P value≤ .05.
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ll growth assays demonstrate that DU145-DTXR cells exhibit
creased sensitivity to olaparib versus control cells (Figure 3B). Wegure 4. Inhibition of ABCB1 expression or function resensitizes TaxR ce
sponse to olaparib in TaxR-shABCB1 cells versus TaxR-Control cells. We
bulin served as a loading control. (B) Cell growth assaywasused to test re
olony formation assays were used to test response to elacridar (0.25 μM)
own (right panel). C = control (DMSO), Elac = elacridar, Ola = olaparibso found very little response to olaparib inCabR cells (Figure 3C). These
ta suggest that overexpression of ABCB1 is associated with resistance to
aparib in CRPC.lls to olaparib treatment. (A) Cell growth assay was used to assess
stern blot was used to assess ABCB1 expression in these cell lines.
sponse to elacridar (0.5μM), olaparib (1μM), or both in TaxRcells. (C)
, olaparib (1 μM), or both in TaxR cells. Quantification of the assay is
, Ab = antibody used, * = P value≤ .05.
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Figure 5. Elacridar resensitizes DU145-DTXR and CabR cells to olaparib treatment. Cell growth assays were used to test response to
elacridar (0.5 μM), olaparib (10 μM for DU145-DTXR or 5 μM for CabR), or a combination of both in (A) DU145-DTXR cells and (B) CabR
cells. C = control (DMSO), Elac = elacridar, Ola = olaparib, * = P value ≤ .05.
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BCB1 in TaxR cells using a shRNA targeting ABCB1 (TaxR-
ABCB1 cells) resensitizes taxane-resistant cells to both docetaxel
d cabazitaxel [13,16]. To test the role of ABCB1 in mediating
oss-resistance to olaparib, we assessed response to olaparib
eatment using the same TaxR-shABCB1 cells (Figure 4A). Western
ot confirms decreased ABCB1 expression in TaxR-shABCB1 versus
GFP expressing TaxR-control cells. Cell growth assays demonstrate
at decreased ABCB1 expression leads to increased sensitivity to
aparib. These data taken together suggest that increased ABCB1
pression can induce resistance to olaparib in CRPC.
harmacologic Inhibition of ABCB1 Activity Resensitizes
axane-Resistant Cells to Olaparib Treatment
We've demonstrated that increased ABCB1 expression can mediate
aparib cross-resistance in taxane-resistant CRPC cells. Inhibition ofgure 6. Combination of olaparib with enzalutamide is more effective than
sponse toenzalutamide, olaparib, or both in (A) TaxRcells (enzalutamide, 1
), and (C) C4-2B cells (enzalutamide, 20 μM; olaparib, 0.5 μM). C = contBCB1 using small molecule drugs could provide novel treatment
rategies capable of rendering resistant tumors sensitive to olaparib
eatment. To test this idea, we used elacridar, a small molecule inhibitor
ABCB1. We've previously shown that elacridar inhibits ABCB1
TPase activity and greatly diminishes ABCB1 function leading to
hanced sensitivity to taxanes [13,16,19]. Cell growth assays
monstrate that combination of elacridar with olaparib is synergistic
d resensitizes TaxR cells to olaparib treatment (Figure 4B). Colony
rmation assays further demonstrate that elacridar is highly efficacious in
mbination with olaparib (Figure 4C). We also show that elacridar can
sensitize both DU145-DTXR and CabR cells to olaparib treatment
igure 5, A and B). These data suggest that small molecule ABCB1
hibition could be a viable strategy in combination with olaparib in the
tting of ABCB1 mediated taxane resistance.
Interestingly, we've previously shown that the antiandrogens
calutamide and enzalutamide possess secondary function aseither single-agent treatment. Cell growth assays were used to test
0μM;olaparib, 1μM), (B)CabRcells (enzalutamide, 10μM;olaparib, 5
rol (DMSO), Enz = enzalutamide, Ola = olaparib, * = P value≤ .05.
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Translational Oncology Vol. 12, No. 7, 2019 Mechanisms of Olaparib-Taxane Cross-Resistance Lombard et al. 877hibitors of ABCB1 ATPase activity [19]. Both are capable of
creasing ABCB1 function and resensitizing taxane-resistant cells to
xane treatment [13,19]. As enzalutamide is currently preferred to
eat taxane-resistant CRPC, we sought to test whether treatment
ith enzalutamide can resensitize taxane-resistant cells to olaparib
0]. Cell growth assays demonstrate that combination treatment
ith enzalutamide and olaparib is more effective in reducing viability
an either treatment alone in both TaxR and CabR cells (Figure 6, A
d B). These data suggest that combining olaparib with a current
RPC standard-of-care drug in enzalutamide may be more beneficial
an a single agent in the context of taxane resistance.
laparib Combined with Enzalutamide Is More Effective than
ngle-Agent Treatment in Olaparib-Sensitive C4-2B Cells
Lastly, we sought to explore the putative combination therapy of
zalutamide and olaparib in the nonresistant setting. It is hypothesized
at next-generation antiandrogens, such as enzalutamide, may produce
tter responses in combination with PARP inhibitors earlier in CRPC
sease progression before the development of resistance. Cell growth
says demonstrate that combination of enzalutamide with olaparib
nificantly reduces C4-2B cell viability versus either single agent
eatment (Figure 6C). Thus, novel combination treatments may provide
nificant benefit to patients earlier in their disease progression prior to
e development of therapeutic resistance.
iscussion
the present study, we test the efficacy of the PARPi olaparib in
odels of treatment-resistant CRPC. We find that docetaxel-resistant
axR cells display robust cross-resistance to olaparib versus parental
4-2B cells. In contrast, AbiR cells remain sensitive to treatment,
hile MDVR cells are moderately cross-resistant to olaparib. These
sults suggest that PARPi efficacy may be altered by previous lines of
erapy, thus raising the need for further study into rational treatment
quencing and the creation of combination therapies.
As TaxR cells demonstrated the most striking insensitivity to olaparib,
e further explored the mechanism by which cross-resistance exists. Our
ta support the role of ABCB1 as a significant factor in determining
nsitivity to olaparib. We show that two disparate docetaxel-resistant
odels, TaxR and DU145-DTXR, display augmented levels of ABCB1
d have a poor response to olaparib, which can be overcome by
hibition of ABCB1 expression or function via elacridar or enzalutamide.
hese data suggest that patients who have developed ABCB1-mediated
sistance to taxanes, which are commonly used for the treatment of
RPC, may fare poorly on subsequent olaparib treatment. We also show
at a model of cabazitaxel-resistant CRPC in the postdocetaxel setting
rther augments ABCB1 levels and is highly resistant to olaparib, which
n be overcome using pharmacologic ABCB1 inhibition. Thus, even in
vanced taxane resistance, blocking ABCB1 activity could be an effective
erapeutic strategy. Previous reports have shown that olaparib resistance
n be developed through ABCB1 overexpression in breast and ovarian
ncers, which could be reversed using ABCB1 inhibitors [21,22]. These
ta support our study suggesting ABCB1 inhibition strategies could be
neficial for resistant tumors.
We've previously shown that the antiandrogen drug enzalutamide
s a secondary function as an inhibitor of ABCB1 activity [19]. In
is study, we show that combination of olaparib with enzalutamide is
ghly effective over single-agent treatment in taxane-resistant cells,
esumably through inhibition of ABCB1 and resensitization to
aparib. As enzalutamide is already approved to treat docetaxel-sistant prostate cancer, our study suggests that combination therapy
ay be preferred over single-agent treatment [23]. We also show that
zalutamide in combination with olaparib is more effective than
ther single agent in olaparib-sensitive C4-2B cells. A previous study
monstrated that enzalutamide could reduce the expression of
veral genes involved in DNA repair and homologous recombina-
n, thus inducing a more sensitive phenotype which provides a
tionale for this combination [24]. It has also been demonstrated
at PARP promotes AR signaling, which is thought to be mediated
aiding AR access to the chromatin [25]. Thus, inhibition of PARP
ith a PARPi drug and the addition of an antiandrogen may synergize
inhibit AR signaling and prostate cancer growth and survival. The
mbination of a PARPi with a taxane has also been shown to work
tter than single-agent treatment in treatment-naive CRPC [25].
hese data taken together suggest that combination therapies of
rrently used agents with novel PARPis may be more efficacious
front prior to exposure to any other single treatment.
We've previously provided evidence for cross-resistance between
rrently available treatments for CRPC [12,13]. Here, we tested for
e potential for cross-resistance between olaparib and these therapies.
s PARPis advance through clinical trials toward approval for prostate
ncer, our data have important and timely clinical implications.
laparib has now received FDA breakthrough therapy designation
sed on results of the TOPARP-A trial. However, it should be noted
at the participants of the TOPARP-A trial were heavily pretreated
1]. Interestingly, 100% of the participants of the trial had
eviously been given docetaxel, 96% had been given abiraterone,
% had been given cabazitaxel, and 28% had received enzalutamide.
hile it appears abiraterone has a minimal effect on olaparib
eatment, our findings suggest that previous therapeutic exposure to
xanes and enzalutamide may have precluded some patients from
sponding to olaparib or may have blunted their response. It will be
portant to conduct further research and clinical trials to understand
e optimal sequencing of all available treatments as, currently,
aparib is being studied for those patients who have already had
cetaxel and either enzalutamide or abiraterone. In addition to
aparib, rucaparib has also recently received the FDA breakthrough
erapy designation based on results of the TRITON2 trial.
owever, the patient indication is the same regarding previous
erapy exposure. Further study of PARPi resistance mechanisms will
rther our understanding of how best to use these drugs.
In conclusion, our study shows that meaningful cross-resistance
ay exist between olaparib and currently administered drugs for
RPC. We specifically focus on robust cross-resistance between
aparib and taxanes and show that olaparib resistance may be
ediated by increased ABCB1 expression, which can be overcome
rough inhibition of ABCB1 expression or function. Future research
to the PARP family and PARPi function will bring key advances in
e field of prostate cancer treatment.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.tranon.2019.04.007.
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